Clinical trials: Hemosiderosis
Iron Overload
Iron Overload in Stem Cell Transplant Recipients
The goal of this study is to examine the impact of iron overload in patients undergoing a bone marrow transplant. We believe that the iron status in these patients is associated with complications for transplant survivors.
- Trial name
- NCT00806715
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston Children's Hospital
Hemochromatosis
Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy
In this project we plan to evaluate the effectiveness of erythrocytapheresis against phlebotomy, both regarding the impact on the reduction in iron overload as well as reduction in patient "burden".
- Trial name
- NCT00202436
- Testing
- Phlebotomy, Erythrocytapheresis
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Sanquin Research & Blood Bank Divisions
Hereditary Haemochromatosis
Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis
Patients with hereditary haemochromatosis will be interviewed/questioned about their Quality of life and the delivered quality of care in the hospital.
- Trial name
- NCT01991925
- Testing
- Interviews, questionaires, RAND-modified delphi method round
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Iron Overload, Hemochromatosis
Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
The purpose of this multi-site research is to validate a rapid magnetic resonance based confounder-corrected R-2 mapping method as a quantitative imaging biomarker of liver iron concentrations.
- Conditions
- Iron Overload, Hemochromatosis, Hemosiderosis
- Trial name
- NCT02025543
- Testing
- MRI
- Where
- 4 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Dysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis
Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.
Dysmetabolic iron overload syndrome and genetic hemochromatosis are frequent causes of iron overload. Polyphenols are efficient iron-chelators.
- Conditions
- Dysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis, Iron Absorption, Polyphenols
- Trial name
- POLYFER (NCT03453918)
- Testing
- polyphenols
- Where
- France
- Volunteers
- 41 people
- Sponsor
- University Hospital, Clermont-Ferrand
Anemia
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
- Trial name
- NCT00466063
- Testing
- Deferasirox
- Where
- 23 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Hemochromatosis
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration
The purpose of this study is to determine if a new MR pulse sequence is accurate in determining how much iron is in the liver.
- Trial name
- NCT00587535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary…
- Trial name
- NCT07332091
- Testing
- Vamifeport
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- CSL Behring
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Anemia, Sickle Cell
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
- Trial name
- NCT00067080
- Testing
- ICL670, deferoxamine
- Where
- 34 sites in United States
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Iron Overload, Hereditary Hemochromatosis
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
Brief Summary: This study was designed to explore a safe dose and characterize the preliminary safety and efficacy of ICL670 in adult patients with previously documented history of homozygous C282Y.
- Trial name
- NCT00395629
- Testing
- Deferasirox (ICL670)
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Anemia, Hemosiderosis
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
A 1-year randomized Phase II core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years of age and older.
- Trial name
- NCT00303329
- Testing
- Deferasirox
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 184 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deposition, Dialysis
Iron Deposits in the Pancreas by MRI Method of Dialysis Patients With Hemosiderosis Iatrogenic (ERDFP)
Recently, a multidisciplinary scientific conference proposed to consider iron overload in dialysis patients as pathological only in the event of demonstration of radiological (in MRI), pancreatic or cardiac ferric deposits.
- Conditions
- Iron Deposition, Dialysis, Iatrogenic Hemosiderosis
- Trial name
- ERDFP (NCT05593068)
- Testing
- MRI
- Where
- France
- Volunteers
- 185 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Hemochromatosis, Iron Overload
Iron Overload in African Americans
Iron overload (hemochromatosis) is a condition which causes the intestines to take too much iron into the body from food or pills. The extra iron can build up in the liver, heart, joints, pancreas, sex organs, and other organs.
- Trial name
- NCT00001455
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Beta-Thalassemia
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood…
- Trial name
- NCT00061750
- Testing
- ICL670, deferoxamine
- Where
- 7 sites in United States
- Volunteers
- 595 people
- Sponsor
- Novartis Pharmaceuticals
Blood Disease, Hemochromatosis
Hemochromatosis--Genetic Prevalence and Penetrance
To examine the cost effectiveness of hereditary hemochromatosis (HH) screening in primary care.
- Trial name
- NCT00006312
- Sponsor
- University of Rochester
Hemochromatosis
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine
- Trial name
- NCT00349453
- Testing
- Deferiprone (L1), Desferrioxamine
- Where
- 13 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Lipomed
Haemochromatosis
Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis
Patients in maintenance treatment for HFE hemochromatosis since at least one year will be included in a two year study period and randomized in two groups experimental and control group.
- Trial name
- Quali-SAT (NCT04779593)
- Testing
- Clinical examination, SF36 questionnaire, AIMS2_SF questionnaire
- Where
- 12 sites in France
- Volunteers
- 239 people
- Sponsor
- Rennes University Hospital
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Iron Overload, Hemosiderosis
Non-invasive Quantification of Liver Iron With MRI
The purpose of this study is to validate magnetic resonance imaging as a biomarker of hepatic iron concentration (HIC). Excessive accumulation of iron in the body is highly toxic, specifically in the liver.
- Trial name
- NCT01516853
- Testing
- Non-contrast MRI
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison